SEC Comment Letter 0000000000-24-002085 to ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682) (NDRA)
ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)
Date: Feb. 23, 2024 · CIK: 0001681682 · Accession: 0000000000-24-002085
AI Filing Summary & Sentiment
File numbers found in text: 333-277058
Letter
United States securities and exchange commission logo February 23, 2024 Francois Michelon Chief Executive Officer ENDRA Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor, MI 48105 Re:ENDRA Life Sciences Inc. Registration Statement on Form S-3 Filed February 14, 2024 File No. 333-277058 Dear Francois Michelon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Benjamin Richie at 202-551-7857 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Coleman Wombwell
Show Raw Text
United States securities and exchange commission logo
February 23, 2024
Francois Michelon
Chief Executive Officer
ENDRA Life Sciences Inc.
3600 Green Court, Suite 350
Ann Arbor, MI 48105
Re:ENDRA Life Sciences Inc.
Registration Statement on Form S-3
Filed February 14, 2024
File No. 333-277058
Dear Francois Michelon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Benjamin Richie at 202-551-7857 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Coleman Wombwell